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Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are included in 
international guidelines as important alternatives to vitamin K antagonists (VKAs) for 
the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). 
Meanwhile, in the Netherlands, NOACs are widely used next to VKAs. The objective of this 
study is to estimate the cost-effectiveness of treatment with NOAC rivaroxaban compared 
to VKA in patients with AF in the Netherlands, using real-world data.
Methods: A decision tree model was developed based on the XANTUS (NCT01606995) 
international prospective observational real-world study. The one-year cost-effectiveness of 
rivaroxaban use, compared to VKAs, was explored in a hypothetical population consisting 
of 2,000 patients with AF (base case) as well as for two additional scenarios, assessing the 
effect of two subpopulations: patients with AF with unstable international normalized ratio 
(INR), defined as the time in therapeutic range < 60% (scenario A), and patients with AF 
who are self-measurers and self-managers of their INR (scenario B).
Results: In the base case, rivaroxaban costs €2.89 while gaining 0.018 quality-adjusted life 
year (QALY) per patient compared to VKA, resulting in an incremental cost-effectiveness 
ratio (ICER) of €157/QALY. In scenario A (unstable INR) and scenario B (self-measurers/
self-managers) rivaroxaban even saved €67.25 and €179.14 per patient, respectively. In the 
base case analysis, the probabilistic sensitivity analysis showed a probability of 47.0% for 
rivaroxaban being dominant (less costly, while gaining QALYs) and 99.8% at a willingness-
to-pay threshold of €20,000/QALY.
Conclusions: In the general Dutch population with AF and the subpopulations with 
unstable INR and self-measurers/self-managers, rivaroxaban treatment is likely to be cost-
effective and a potentially cost-saving alternative to VKA.
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Introduction
Atrial fibrillation (AF) is a disease associated with blood clot formation, which can be 
prevented by anticoagulation therapy. Vitamin K antagonists (VKAs) are mainly used 
as standard anticoagulation therapy in the Netherlands. Non-vitamin K antagonist oral 
anticoagulants (NOACs) have been included in international guidelines as an important 
alternative to VKAs [1]. The European Society for Cardiology guidelines recommend 
NOACs in preference to VKAs when oral anticoagulation is initiated in a patient with 
AF who is eligible for a NOAC [1]. According to the medical report of the Federation of 
Dutch Thrombosis Service (FNT), a total of 296,343 patients with AF were anticoagulated 
with either acenocoumarol or phenprocoumon (VKAs) in the year 2015 [2]. The Dutch 
reimbursement authorities presume the safety and effectiveness of acenocoumarol, and 
phenprocoumon is comparable to warfarin, which is the most used VKA worldwide [3]. 
Recent years, however, have shown a steady increase in patients who are treated with a 
NOAC instead of VKAs [2].
AF is a disease characterized by an irregular heart rate. The arrhythmia is caused 
by a “circle stimulus” which leads to uncoordinated atrial activity. This causes stagnation 
of the blood flow in the atria, leading to blood clot formation [4]. As a result, patients 
who are diagnosed with AF have an increased risk of thromboembolic events. AF doubles 
the risk of heart-related death and is associated with a five-fold increased risk of stroke 
[5]. Furthermore, these clots are also known to block other arteries, causing systemic 
embolisms or myocardial infarctions [6].
The major drawback of the VKAs is that they have a very narrow therapeutic 
window which can be impacted by many drug and food interactions. For this reason 
VKAs require frequent monitoring of the international normalized ratio (INR) of the 
patients [2,7]. In the Netherlands, the INR monitoring is managed and controlled by a 
specialised thrombosis service.
NOACs have become available as a possible alternative to VKAs for prevention of 
stroke and systemic embolism in atrial fibrillation patients in the Netherlands since 2012 
[8,9]. Due to the predictable pharmacokinetics and -dynamics of these drugs, routine INR 
monitoring is no longer required [10]. NOACs have a prominent place in international 
guidelines for several years now [1]. In September 2016, the Dutch association for general 
practitioners (NHG, Nederlands Huisartsen Genootschap) issued a statement stating 
that anticoagulant treatment with NOACs is equally adequate as VKAs concerning the 
indications AF and VTE [11]. The FNT has reported a decrease in the number of patients 
who started a VKA for the first time in 2015. As a reason for this decrease, the FNT states 
that this is mainly due to the steady increase in NOAC prescriptions [2].
One of these NOACs, rivaroxaban, has proven to be at least as effective and safe as 
VKAs in the ROCKET-AF (NCT00403767) clinical trial [12]. Recently, also an international 
prospective observational study with real-world data has been published on the 
effectiveness and safety of rivaroxaban. This single-arm study, XANTUS (NCT01606995), 





The objective of this analysis is to estimate the cost-effectiveness of treatment 
with rivaroxaban compared to VKA in patients with AF, using real-world data from the 
XANTUS study.
Methods
A model was developed with a time horizon of one year, populated with patients from the 
real-world study XANTUS (NCT01606995) [13]. The cost-effectiveness was explored in 
three subgroups: general Dutch population with AF, patients with AF with unstable INR 
and patients with AF using INR self-measuring or self-management devices (Table 1). For 
example, the subgroup of patients with unstable INR is chosen separately, as these patients 
can be assumed to have a higher INR measurement frequency, which is associated with 
higher costs [2]. Unstable patients were assumed to have a time in therapeutic range 
(TTR) of < 60% which was consistent with 16% of the total hypothetical population, based 
on 3,978 patients in the Euro Heart Survey on AF with complete follow-up [14]. The 
hypothetical cohort was based on a previously published study (XANTUS) and, therefore, 
a formal ethics review committee approval and consent of patients was not needed. The 
primary result of the cost-effectiveness analysis is the incremental cost effectiveness ratio 
(ICER), presented in costs per quality-adjusted life year (QALY). Sensitivity analyses were 
conducted to show the robustness of the model.
Table 1. Different populations taken into consideration for the cost-effectiveness 
analysis of rivaroxaban versus VKA.
Scenario Included patient population
Base-case AF
A AF with unstable INR group (TTR < 60%)
B AF only self-measures/self-managers of INR
Abbreviations: AF, atrial fibrillation; INR, international normalized ratio; TTR, time in therapeutic range.
The model
Transition probabilities were based on a comparison of the XANTUS and ROCKET-AF 
studies [12,13]. In the ROCKET-AF study, the control group is treated with warfarin, 
which is a VKA that is not available in the Netherlands. Because therapy with warfarin, 
acenocoumarol, and phenprocoumon all depend on dose adjustments based on patient INR 
values, their safety and efficacy are considered the same and, therefore, the ROCKET-AF 
study data can be considered reflective of the Dutch situation including the comparator 
therapy [3]. Treatment with rivaroxaban and VKA were continued during the one-year 
time horizon of the model, which is line with the duration of the XANTUS trial [13].
The patient populations of the rivaroxaban arm of both studies were matched in 
order to account for the differences in characteristics [15]. The rivaroxaban arm of the 
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XANTUS trial comprised 60.5% of patients aged 75 years or greater and 25.5% between 
the age of 65 and 75. Of this same population, 50.6% had a CHADS2 (Congestive Heart 
Failure, Hypertension, Age (≥75 years), Diabetes Mellitus, prior Stroke/transient ischaemic 
attack) score of 2, 27.6% had a score of 3, and 21.8% had a score of 4 or higher [15]. With 
this correction, represented as the Matching Adjusted Indirect Comparison (MAIC ratios), 
the rivaroxaban transition probabilities of the ROCKET-AF reflect the XANTUS results. 
Application of the MAIC ratio was only possible for primary endpoints listed by the study of 
Camm et al. [15]. Therefore, we only included health states based on the primary endpoint 
presented in this comparative study, namely: ‘no event’, ‘myocardial infarction’, ‘ischaemic 
stroke’, ‘major bleeding’, ‘vascular death’ and ‘death by any cause’ (Figure 1). The transition 
probabilities are shown in Table 2.




Table 2. Transition probabilities used in the model.
Transition probability Value (range) Source
Transition probability 
VKA
RR rivaroxaban versus 
VKA
No event 0.9151 (fixed) 1.0109 (0.6048 – 1.0208) [15]
Ischaemic stroke 0.0196 (0.0165 – 0.0230) 0.7661 (0.5962 – 0.9843) [15]
Myocardial infarction 0.0112 (0.0089 – 0.0138) 0.6663 (0.4710 – 0.9424) [15]
Major bleeding 0.0340 (0.0299 – 0.0383) 0.9106 (0.7610 – 1.0896) [15]
Vascular death 0.0171 (0.0142 – 0.0202) 1.0647 (0.8325 – 1.3617) [15]
Death any cause 0.0030 (0.0019 – 0.0044) 1.0893 (0.6048 – 1.9620) [15]
Abbreviations: RR, relative risk; VKA, vitamin K antagonist.  
Costs
The patients were treated with 15 mg or 20 mg rivaroxaban once daily [16]. The costs 
of VKAs were based on a weighted average of the use of acenocoumarol (5 mg) and 
phenprocoumon (3 mg) in 2014, estimated at 77% and 23%, respectively [17]. All drug 
costs were based on the Dutch price list [18].
Based on the 2015 annual medical report of the FNT, a distinction was made 
between measurement at the thrombosis service, at home, and self-measurement/self-
management [2]. The INR should be within the range of 2.0–3.5. The costs of a vascular 
death were assumed to be equal to the costs of one visit to an emergency room [19]. 
All costs were based on the societal perspective and corrected to the year 2016. A total 
overview of the event-related costs is shown in Table 3.
Table 3. Event costs used in cost-effectiveness analysis.
Event Costs Range Source
Ischaemic stroke €37,966 €30,373 – €45,559 [20]
Major bleeding €5,072 €2,033 – €13,847 [21]
Myocardial infarction acute €5,117 €5,030 – €5,203 [22]
Myocardial infarction long-term (monthly) €200 €186 – €210 [22]
Vascular death €261 €209 – €314 [23]
Death by any cause - Fixed
A complete overview of the utilization and costs associated with the treatment of VKA 
and rivaroxaban is shown in Table 4, as well as the frequency of INR measurements per 
year. To calculate the mean number of INR measurements for stable or unstable patients 
with AF in one year, the following formula is used:
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The median number of correctly dosed (stable) patients with AF is 80.2% [2].
Table 4. Resource utilization and costs.
Parameter Mean Range Source
Number of INR measurements per year
Median 20.80 Fixed [2]
Stable patients 20.27 Fixed [2]
Unstable patients 25.97 Fixed [2]
INR measuring costs
Initiation of SM (first quartile) €377.11 €301.69 – €452.53 [19]
SM (per quartile) €182.84 €146.27 – €219.41 [19]
INR control (at home) €28.79 €23.03 – €34.55 [19]
INR control (near-patient, per quartile) €190.90 €152.72 – €229.08 [19]
Traveling costs (per km) €0.50 €0.40 – €0.60 [23]
Drug costs
VKA €0.09 Fixed [18]
Rivaroxaban €2.29 Fixed [18]
Length of hospitalization (days)
VKA 3.02 Fixed [24]
Rivaroxaban 2.11 Fixed [24]
Hospitalization costs
Hospitalization costs (per day) €447.07 €223.54 – €647.90 [23]
Outpatient clinic costs (per visit) €80.47 €64.59 – €96.88 [23]
General practitioner (per visit) €33.30 €26.64 – €39.96 [23]
Emergency room visit (per event) €261.38 €209.10 – €313.66 [23]
Group unstable INR 16% Fixed [2]
Abbreviations: INR, international normalized ratio; SM, self-measurement; VKA, vitamin K antagonist.
Utilities
A baseline utility was used for the ‘no event’ health state. The impact of all possible events 
on the patients’ quality-of-life was taken into account (Table 5). Upon the occurrence of 
certain events a (dis)utility for a specific time range was used to calculate quality-adjusted 




mild, moderate or severe event. The utilities of the health states ‘vascular death’ and ‘death 
by any cause’ were assumed to be equal to zero.
Table 5. Utilities used in the cost-effectiveness analysis.
Parameter Mean Range Source
Baseline utility AF 0.6980 0.5542 – 0.8242 [22]
Ischaemic stroke mild 0.6704 0.5337 – 0.7937 [22]
Ischaemic stroke moderate 0.6165 0.4929 – 0.7328 [22]
Ischaemic stroke severe 0.4416 0.3562 – 0.5287 [22]
Ischaemic stroke average 0.5762 Fixed [22]
Myocardial infarct 0.5328 0.4281 – 0.6360 [22]
Major bleeding 0.7000 0.5006 – 0.8659 [21]
Medication
Rivaroxaban 0.9730 Fixed [25]
VKA 0.9480 Fixed [26]
Abbreviations: AF, atrial fibrillation; VKA, vitamin K antagonist.
Sensitivity analyses
In order to determine the effect of uncertainty around input parameters we performed 
a probabilistic sensitivity analysis (PSA). The distributions applied on the 95% confidence 
interval (CI), or if a 95%CI was not available a range of 20%, of the input parameters were 
beta for probabilities and utilities, normal for relative risks and differences, and gamma 
for costs. For the three different populations a PSA was performed using a Monte Carlo 
simulation with 2,000 iterations. Results were plotted in a cost-effectiveness plane with a 
willingness-to-pay (WTP) threshold of €20,000/QALY. These results were used to produce 
cost-effectiveness acceptability curves (CEACs). Additionally, a one-way sensitivity analysis 
was conducted to determine which parameters have the biggest influence on the ICER of 
the base case analysis.
Results
Cost-effectiveness analysis
The deterministic results of the three populations for VKA and rivaroxaban are shown in 
Table 6. Rivaroxaban was not only cost-effective at this threshold but even cost-saving in 
the populations assessed in scenario A and B. In the base case analysis rivaroxaban leads to 
health gains of 0.018 QALY and costs of €48.44 per patient, compared to VKA, resulting 
in an ICER of €2,628/QALY. Scenarios A and B showed a dominant ICER, with savings of 
€21.71 and €133.59 per patient with AF.
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Table 6. Deterministic costs, effects and incremental cost effectiveness ratios per 
patient of the three selected populations.
Costs Effects (QALYs) Incremental
VKA Rivaroxaban VKA Rivaroxaban Costs Effects 
(QALY)
ICER
Base case €1,609 €1,657 0.639 0.658 €48.44 0.018 €2,628/QALY
Scenario A €1,679 €1,657 0.639 0.658 €-21.71 0.018 Dominant
Scenario B €1,791 €1,657 0.639 0.658 €-133.59 0.018 Dominant
Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; VKA, vitamin K 
antagonist.
Sensitivity analyses
For all three populations, a PSA was executed with 2,000 iterations. The cost-effectiveness 
plane for the base case analysis is shown in Figure 2. The other cost-effectiveness planes 
are presented in Appendix Figures A1–A2. The probability of being cost-effective at a 
WTP threshold of €20,000/QALY is 99.8% in the base case and 100% in the two other 
scenarios. Compared to a WTP threshold of €0/QALY, rivaroxaban use in the base case 
analysis has a probability of 25.7% of being cost-saving compared to VKA treatment. The 
probabilities of being cost-saving for scenarios A and B were 57.4%, and 88.1% respectively. 
The corresponding CEACs are displayed in Figure 3.
Results of the one-way sensitivity analysis in the base case analysis are shown in 
Table 7, representing the ten parameters with the biggest influence on the ICER. The 
relative risk of rivaroxaban versus VKA for ischaemic stroke, the costs of INR monitoring at 
home and the costs of ischaemic stroke were the parameters with the biggest influence on 
the ICER, but the ICERs remained either cost-saving (dominant) or cost-effective compared 




Figure 2. Probabilistic sensitivity analysis of the base-case scenario. Abbreviation: 
QALY, quality-adjusted life year.
Figure 3. Cost-effectiveness acceptability curve of the base case analysis, and 
scenarios A and B. Abbreviations: CE, cost-effective; CEAC, cost-effectiveness acceptability curve; QALY, 
quality-adjusted life year; VKA, vitamin K antagonist.
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RR rivaroxaban versus VKA – Ischaemic stroke  Dominant  €10,484
Costs – INR control (at home)  €4,795  €236
Costs – Ischaemic stroke  €4,421  €648
Transition probability VKA – Ischaemic stroke  €4,048  €1,032
Costs – SM (per quartile)  €3,875  €1,251
RR rivaroxaban versus VKA – Other death  Dominated  €1,972
RR rivaroxaban versus VKA – Major bleeding  €1,511  €3,514
Costs – Major bleeding  €3,302  €1,410
RR rivaroxaban versus VKA – Myocardial infarction  €1,814  €3,666
Costs – Travel costs (per km)  €3,347  €1,834
Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RR, relative risk; SM, 
self-measurement/-management; VKA, vitamin K antagonist.
Discussion
In the base case analysis, rivaroxaban treatment was associated with a gain of 0.018 
QALY and extra costs of €48.44 per patient over a period of one year compared to 
VKA treatment, resulting in an ICER of €2,628/QALY. These results suggest that, in the 
base case, rivaroxaban is cost-effective compared to VKA for patients with AF at a WTP 
threshold of €20,000/QALY. In the scenarios including patients with unstable INR and 
self-measurers/self-managers, the use of rivaroxaban provided cost savings and health 
gains compared to VKA.
To our knowledge this is the first Dutch economic evaluation of rivaroxaban vs VKA 
based on real-world data, whereas most cost-effectiveness studies are based on clinical trial 
data. The input parameters for the INR measurement were also obtained from real-world 
data of the Dutch thrombosis service, as documented in the FNT medical annual report 
[2]. Still, there are some uncertainties and limitations to be discussed.
The therapeutic and target range for INR in the Netherlands was not similar to 
the international range (2.5–3.5 vs 2.0–3.0). The FNT has recently decided to adjust the 
therapeutic INR range to reflect the international values [27]. Given this, we assumed that it is 
not necessary to extrapolate the INR values from the XANTUS, and ROCKET-AF studies to 
the Dutch situation. The XANTUS study has Dutch data available, however it was not suitable 
for this analysis because of the absence of a control group [28]. We compared results from 
the total XANTUS population [13] to the Dutch XANTUS subpopulation [28], and found the 




1.6% vs 1.4%, respectively). The number of non-major bleedings was slightly lower in the total 
XANTUS population compared to the Dutch XANTUS subpopulation: 12.9% vs 15.8%.
The XANTUS study did not include a control group. To overcome this problem, 
data from the analysis of Camm et al. [13] were used to make a comparison between the 
XANTUS and ROCKET-AF studies [15]. The MAIC ratio was used to convert transition 
probabilities of the rivaroxaban arm from the ROCKET-AF trial to resemble the results 
in the real-world. This leads to an indirect comparison which is a limitation, but, because 
there was no control group included in the XANTUS study, it was the only way to make 
a reasonable assumption. Also, because the study of Camm et al. [15] only included five 
primary outcomes as shown in Figure 1, the comparison was limited to these outcomes and 
it was not possible to include, for example, the severity of an ischaemic stroke (e.g. mild, 
moderate, stroke) or major bleeding (e.g. intracranial vs non-intracranial haemorrhage). 
These factors might have contributed to either an over- or underestimation of the ICER.
On another note, it can be discussed that the one-year time horizon might not be 
ideal for modelling a population suffering from AF, since this is a chronic disease requiring 
lifelong treatment, as well as being associated with significant cardiovascular complications. 
Therefore, a model which includes the entire lifespan of the patients suffering from AF 
might give more informative results.
Our results are more favourable for rivaroxaban compared to results from other 
studies performed in Belgium and Germany [29,30]. This might be caused by the fact 
that the other studies are both only based on the clinical trial data from the ROCKET-AF 
study and that XANTUS study shows a more positive outcome for rivaroxaban. Another 
explanation could be that the drug costs of rivaroxaban have decreased substantially since 
these studies were published. This is a major contributor to the cost of the treatment 
and, for our study, we have used a cost of €2.29 (including VAT) per 15 mg or 20 mg 
rivaroxaban, whereas the Belgian and German studies used €2.70 and €3.26, respectively. 
The use of €2.29 in our study is based on data from the Dutch Healthcare Institute, which 
shows the price before a discount is agreed upon by the government and the manufacturer 
(list price) [18]. This makes it a conservative assumption; the price could in fact be lower, 
which may cause an overestimation of our ICER. However, price negotiations regarding 
the costs associated with the thrombosis service occur as well, which could mean an 
underestimation of the ICER. Moreover, differences between INR values, risk factors of 
patients, clinical outcomes, and differences in social health costs may explain differences of 
cost-effectiveness results between countries.
Conclusions
In conclusion, treatment with rivaroxaban was cost-effective or even cost-saving and 
provided health gains compared to treatment with a VKA in the general Dutch population 
with AF, as well as the other examined populations patients with unstable INR (scenario A), 
and self-measurers/self-managers (scenario B). In sensitivity analysis, the model has shown 
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to be robust. At a WTP threshold of €20,000/QALY, rivaroxaban appeared to be 99.8% 





Figure A1. Probabilistic sensitivity analysis of scenario A, AF with unstable INR 
group (TTR < 60%). Abbreviation: QALY, quality-adjusted life year.
Figure A2. Probabilistic sensitivity analysis of scenario B, AF with only self-
measures and self-managers. Abbreviation: QALY, quality-adjusted life year.
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